financetom
Business
financetom
/
Business
/
Upcoming Earnings From Major Hyperscalers to Set Tone for AI Sentiment, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Upcoming Earnings From Major Hyperscalers to Set Tone for AI Sentiment, Oppenheimer Says
Jan 28, 2025 1:11 PM

03:56 PM EST, 01/28/2025 (MT Newswires) -- Upcoming earnings from major hyperscalers are expected to set the tone for near-term sentiment as the market weighs potential changes in artificial intelligence infrastructure spending, Oppenheimer said in a note emailed Tuesday.

Several AI infrastructure-focused stocks fell sharply on Monday as investors responded to China-based startup DeepSeek's faster-performing models and reports of lower training costs, the analysts noted.

Vertiv Holdings ( VRT ) , Modine Manufacturing ( MOD ) , GE Vernova ( GEV ) and Bloom Energy ( BE ) witnessed major drops, while American Superconductor ( AMSC ) , Johnson Controls International ( JCI ) , Trane Technologies ( TT ) , Carrier Global ( CARR ) and Cummins (CMI) also faced pressure, the investment firm said.

Industry orders and price softening are expected in fiscal 2025, while evolving AI capabilities could introduce both fresh uncertainties and long-term growth prospects, according to the note.

DeepSeek's recently launched V3 and R1 models suggest training costs could be significantly reduced. However, there are some doubts on whether headline figures reflect full research and development expenses, according to Oppenheimer.

If training becomes cheaper, the resulting higher AI usage could still boost data center investments, as lower costs may fuel better returns on infrastructure deployments, Oppenheimer noted.

Geopolitical considerations remain pivotal, particularly amid US export controls on high-compute chips, which could spur further policy responses aimed at reclaiming leadership in AI technology.

Investors are closely monitoring forthcoming earnings from Meta (META) and Microsoft ( MSFT ) for any signals on AI roadmap adjustments and whether spending plans shift to H2 or 2026, Oppenheimer said.

Price: 106.11, Change: +3.51, Percent Change: +3.42

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
America Movil Increases Stake in ClaroVTR to 91%
America Movil Increases Stake in ClaroVTR to 91%
Jun 24, 2024
09:48 AM EDT, 06/24/2024 (MT Newswires) -- America Movil ( AMX ) said Monday it has increased its stake in ClaroVTR, its joint venture with Liberty Latin America, to 91%. The company said it increased its ownership by converting its outstanding notes held in ClaroVTR into equity. Financial terms of the increase weren't disclosed. Liberty Latin America will own the...
US Supreme Court takes up 'Dewberry' trademark dispute
US Supreme Court takes up 'Dewberry' trademark dispute
Jun 24, 2024
WASHINGTON (Reuters) - The U.S. Supreme Court on Monday agreed to decide a $43 million dispute between two real estate developers - one in Virginia and one in Georgia - over the rights to the Dewberry name in a case exploring when courts can award a company's profits as a remedy for trademark infringement. The justices took up an appeal...
VCI Global to Invest $30 Million in TalkingData Group Holding
VCI Global to Invest $30 Million in TalkingData Group Holding
Jun 24, 2024
09:45 AM EDT, 06/24/2024 (MT Newswires) -- VCI Global ( VCIG ) said Monday that it signed an agreement to invest up to $30 million in TalkingData Group Holding, which provides big data analytics and artificial intelligence-powered solutions in Asia. The investment will make VCI Global ( VCIG ) a substantial shareholder of TalkingData Group and grant VCI Global (...
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
Jun 24, 2024
Monday, Alnylam Pharmaceuticals Inc ( ALNY ) revealed topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for ATTR amyloidosis with cardiomyopathy (ATTR-CM). ATTR-CM is a type of heart muscle disease that occurs when amyloid fibrils – clumps of misfolded proteins – are deposited into heart tissue and cause it to stiffen. Also...
Copyright 2023-2026 - www.financetom.com All Rights Reserved